RBMS2

Across TCGA pan-cancer cohorts, RBMS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBMS2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBMS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RBMS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and OV show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where RBMS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	1.000	0.344	.009	44	view →
LSCC	DFS	Quartile	II,III,IV	0.415	0.886	.002	39	view →
LUAD	DFS	Median	All	0.893	1.000	.019	5	view →
OV	DFS	Median	All	0.874	0.604	.042	4	view →
CCRCC	OS	Median	All	1.000	0.682	.009	3	view →
PDAC	OS	Quartile	III,IV	0.280	0.584	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBMS2–HNSC (OS)

Open the HNSC breakdown →